Manufacturing capabilities without an approval is not particularly worthwhile. If there is not an approval it has been a waste of shareholder money, but management doesn't seem to care about that after the Advent deal that shareholders still have $45 million to pay for next year and NWBO is struggling along with only ~$5 million in cash.
Market Data 
Markets 
AI
